Compare CNX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | WGS |
|---|---|---|
| Founded | 1860 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 2.6B |
| IPO Year | 1998 | N/A |
| Metric | CNX | WGS |
|---|---|---|
| Price | $41.73 | $76.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $35.78 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 1.9M | 722.0K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $2,239,134,000.00 | N/A |
| Revenue This Year | $0.27 | $29.98 |
| Revenue Next Year | $9.90 | $24.85 |
| P/E Ratio | ★ $10.34 | $1,251.58 |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.68 | $55.17 |
| 52 Week High | $43.62 | $170.87 |
| Indicator | CNX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 39.35 |
| Support Level | $36.33 | $68.55 |
| Resistance Level | $43.62 | $95.94 |
| Average True Range (ATR) | 1.46 | 5.58 |
| MACD | -0.06 | 0.82 |
| Stochastic Oscillator | 69.57 | 31.38 |
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.